A number of recent advances have been made in the clinical diagnosis and prognostication
of multiple sclerosis patients. Future research will enable the development of more accurate …

During the past decades, better understanding of relapsing-remitting multiple sclerosis
disease mechanisms have led to the development of several disease-modifying therapies …

Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …

Importance Accumulation of disability in multiple sclerosis may occur as relapse-associated
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …

Objective Rates of worsening and evolution to secondary progressive multiple sclerosis
(MS) may be substantially lower in actively treated patients compared to natural history …

Importance The mechanisms driving neurodegeneration and brain atrophy in relapsing
multiple sclerosis (RMS) are not completely understood. Objective To determine whether …

Objective Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We
investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …